Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
作者： K S Albain , V W Rusch , J J Crowley , T W Rice , A T Turrisi
DOI: 10.1200/JCO.1995.13.8.1880
关键词:
摘要: PURPOSETo assess the feasibility of concurrent chemotherapy and irradiation (chemoRT) followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) a cooperative group setting, to estimate response, resection rates, relapse patterns, survival for stage subsets IIIA(N2) versus IIIB.PATIENTS AND METHODSBiopsy proof either positive N2 nodes (IIIAN2) or N3 T4 primary lesions (IIIB) was required. Induction two cycles cisplatin etoposide plus chest RT 45 Gy. Resection attempted if response stable disease occurred. A chemoRT boost given unresectable margins found.RESULTSThe median follow-up time 126 eligible patients [75 51 IIIB] 2.4 years. The objective rate induction 59%, 29% were stable. Resectability 85% 80% IIIB group. Reversible grade 4 toxicity occurred 13% patients. There ...
elsevier.com
sci-hub.se 参考文章(50)
Valerie W. Rusch, Kathy S. Albain, John J. Crowley, Thomas W. Rice, Vassyl Lonchyna, Robert McKenna, Robert B. Livingston, Brian R. Griffin, John R. Benfield, Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 105, pp. 97- 106 ,(1993) , 10.1016/S0022-5223(19)33853-X
Clifton F. Mountain, Prognostic implications of the International Staging System for Lung Cancer. Seminars in Oncology. ,vol. 15, pp. 236- 245 ,(1988) , 10.5555/URI:PII:0093775488900450
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
G M Strauss, M P Langer, A D Elias, A T Skarin, D J Sugarbaker, Multimodality treatment of stage IIIA non-small-cell lung carcinoma: A critical review of the literature and strategies for future research Journal of Clinical Oncology. ,vol. 10, pp. 829- 838 ,(1992) , 10.1200/JCO.1992.10.5.829
J Klastersky, J P Sculier, G Bureau, P Libert, P Ravez, G Vandermoten, J Thiriaux, J Lecomte, R Cordier, G Dabouis, Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. Journal of Clinical Oncology. ,vol. 7, pp. 1087- 1092 ,(1989) , 10.1200/JCO.1989.7.8.1087
Nael Martini, Betty J. Flehinger, The role of surgery in N2 lung cancer. Surgical Clinics of North America. ,vol. 67, pp. 1037- 1049 ,(1987) , 10.1016/S0039-6109(16)44341-0
K S Albain, J J Crowley, M LeBlanc, R B Livingston, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology. ,vol. 9, pp. 1618- 1626 ,(1991) , 10.1200/JCO.1991.9.9.1618
E Rapp, J L Pater, A Willan, Y Cormier, N Murray, W K Evans, D I Hodson, D A Clark, R Feld, A M Arnold, Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. Journal of Clinical Oncology. ,vol. 6, pp. 633- 641 ,(1988) , 10.1200/JCO.1988.6.4.633
J D McCracken, L M Janaki, J J Crowley, S A Taylor, P G Giri, G B Weiss, W Gordon, L H Baker, A Mansouri, J P Kuebler, Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. Journal of Clinical Oncology. ,vol. 8, pp. 892- 898 ,(1990) , 10.1200/JCO.1990.8.5.892
R Arriagada, A Kramar, T Le Chevalier, H De Cremoux, Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. Journal of Clinical Oncology. ,vol. 10, pp. 447- 451 ,(1992) , 10.1200/JCO.1992.10.3.447